1 South Prospect
UHC-SATC Room 1407
Burlington, VT 05401
United States
- Ph.D. University of Mississippi
- B.A. University of Memphis
Department of Psychiatry
Vermont Center on Behavior and Health
BIO
Dr. Peck's research interests are two-fold. He has conducted research focused on the development and evaluation of novel treatments for opioid misuse and use disorder. Most recently, this has included work on two randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated opioid use disorder. Dr. Peck also has a research interest focused on the delivery and evaluation of cognitive-behavioral treatments for posttraumatic stress disorder in individuals with concurrent substance use disorders. He is currently preparing to integrate these two areas of research as he directs a study investigating the contribution of prolonged exposure therapy, an efficacious manualized cognitive-behavioral treatment for posttraumatic stress disorder, above and beyond opioid agonist treatment alone for reducing posttraumatic stress disorder symptoms among patients with concurrent posttraumatic stress disorder and opioid use disorder.
Publications
Bio
Dr. Peck's research interests are two-fold. He has conducted research focused on the development and evaluation of novel treatments for opioid misuse and use disorder. Most recently, this has included work on two randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated opioid use disorder. Dr. Peck also has a research interest focused on the delivery and evaluation of cognitive-behavioral treatments for posttraumatic stress disorder in individuals with concurrent substance use disorders. He is currently preparing to integrate these two areas of research as he directs a study investigating the contribution of prolonged exposure therapy, an efficacious manualized cognitive-behavioral treatment for posttraumatic stress disorder, above and beyond opioid agonist treatment alone for reducing posttraumatic stress disorder symptoms among patients with concurrent posttraumatic stress disorder and opioid use disorder.